-
Results for the first quarter 201325 Apr 2013 -
POSITIVE FINAL RESULTS OF PHASE 2B CEVIRA® STUDYResults demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix.10 Apr 2013
-
Updated European Association of Urology Guidelines Strengthen Recommendation on Use of Hexvix®Recognizes Benefit of Hexvix in Reducing Recurrence Rate and Improving Time to Recurrence of Bladder Cancer03 Apr 2013
-
Wall Street Journal Features Visonac Development11 Mar 2013
-
Results fourth quarter and full year 201228 Feb 2013
-
Presentation of Cevira® Phase 2b Results05 Dec 2012
-
PHOTOCURE ANNOUNCES POSITIVE RESULTS OF CEVIRA® STUDYRESULTS DEMONSTRATE SIGNIFICANT EFFICACY IN TREATMENT OF LESIONS AND ONCOGENIC HUMAN PAPILLOMA VIRUS IN PATIENTS WITH PRECANCEROUS LESIONS OF THE CERVIX05 Dec 2012
